TAmiRNA will use the conference to highlight its its proprietary miND® NextGen small RNA-sequencing platform with an array of spike-ins that led to the development of hepatomiR® – Europe´s first CE-IVD marked test to measure microRNA biomarkers of liver function. Together, these assets demonstrate the performance of TAmiRNA´s discovery pipeline for microRNA diagnostic biomarkers.
TAmiRNA will spotlight its miND® NextGen small RNA-sequencing platform and the hepatomiR® test—Europe’s first CE-IVD marked test for liver function microRNA biomarkers—at the Zürich conference. These innovations highlight TAmiRNA’s strengths in microRNA diagnostic development.
Dr. Matthias Hackl, CEO and Chief Scientific Officer, will present “MicroRNAs as a Novel Class of Biomarkers” on Friday, September 6, in Session 6: New Technologies. He will discuss the critical role of miRNA biomarkers and TAmiRNA’s advanced sequencing techniques, which speed up the discovery of novel biomarker associations.
Don’t miss this opportunity to explore TAmiRNA’s latest advancements in microRNA diagnostics.
Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA’s services can assist your business!